China

George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.

George Clinical in China

China is George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.

With its immense potential for patient recruitment and a rapidly growing pharmaceutical market, China, currently the third largest in the world, is an obvious choice for many when entering the Asian market.

The Chinese healthcare delivery system consists of public hospitals and community healthcare centers, with an increasing private care system. Only GCP accredited sites are eligible for running commercial Phase I, II and III studies, and this accreditation can only be achieved by public hospitals in China. The accreditation is issued by the CFDA and NHPFC based upon a site inspection. Accreditation is renewed every 3 years, with a quality review performed by the PFDA every year.

George Clinical has an extensive network of over 260 trial centers in 50 cities for Phase II-IV trials, and a wider network that includes community health centers in semi-urban and rural areas for Phase IV trials.

What are the benefits of conducting clinical trials in China?

  • China has access to a large patient pool
  • Rapidly developing medical infrastructure in urban centres and centres of excellence for many common diseases such as hypertension, diabetes and renal disease
  • Low operational costs

What are the prevalent diseases in China?

  1. Stroke
  2. Ischaemic Heart Disease
  3. Chronic obstructive pulmonary disease
  4. Cancer
  5. Road injury
  6. Hypertension
  7. Diabetes mellitus
  8. Lower respiratory infections

George Clinical China News

最新研究显示:糖尿病患者更易患癌症,女性尤甚

一项涉及约2千万人的全球调查结果表明,糖尿病极易致癌,而女性糖尿病患者的癌症患病率则更高。

Diabetes raises risk of cancer, with women at even greater likelihood, a major new study has found

A global review involving almost 20 million people has shown that having diabetes significantly raises the risk of developing cancer, and for women the risk is even higher.

乔治全球健康研究院(中国)高级研究员当选世界心脏联盟2018新兴领导者

乔治全球健康研究院(中国)卒中部门主任宋莉莉博士、移动健康及伤害部门主任田懋一博士成功当选2018年世界心脏联盟新兴领导者。

Senior Research Fellows from TGI China selected as 2018 Emerging Leaders

Dr Lily Song, Head of Stroke, and Dr Maoyi Tian, Head of Digital Health, at The George Institute China, were successful in being awarded Emerging Leaders by the World Heart Federation (WHF) in 2018. 

中澳研究者齐聚成都,共同推进INTERACT3研究项目

2018年6月8日,INTERACT3研究(急性脑出血包括强化降压的组合性管理研究)首届研究者会议在成都圆满召开。

Experts from Australia and China congregate in Chengdu to promote INTERACT3 study

On 8 June, 2018, the INTERACT3 (INTEnsive care bundle with blood pressure reduction in Acute Cerebral hemorrhage Trial) study’s first investigator meeting was held successfully in Chengdu.  Participants included principal investigators from Australia and China, ...

Contact

George Clinical Address:
Level 18, Tower B, Horizon Tower
Haidian District
Beijing, 100088
P.R. China

2223, 22/F Tomson Commercial Building,
710 Dongfang Road, Pudong District
Shanghai, 200122
P.R. China

Details

Number of Personnel: 50
In-country Services:

Beijing
Project Management, Clinical Operations, Data Management, Medical and Safety Services, Clinical Compliance, Regulatory Services, Statistics, Health Economics

Shanghai
Clinical Operations

Chengdu
Clinical Operations

Harbin
Project Management, Clinical Operations

Population: 1.4 billion
Official Language: Putonghua (Mandarin). Local dialects may be used
Hospital Records Language: Simplified Chinese
Electronic Hospital Records: Currently, paper records are used.

Twitter Facebook LinkedIn